Market Research Logo

Schistosomiasis - Pipeline Review, H2 2016

Schistosomiasis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Schistosomiasis - Pipeline Review, H2 2016’, provides an overview of the Schistosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Schistosomiasis
    • The report reviews pipeline therapeutics for Schistosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Schistosomiasis therapeutics and enlists all their major and minor projects
    • The report assesses Schistosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Schistosomiasis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Schistosomiasis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Schistosomiasis Overview
    Therapeutics Development
    Pipeline Products for Schistosomiasis - Overview
    Pipeline Products for Schistosomiasis - Comparative Analysis
    Schistosomiasis - Therapeutics under Development by Companies
    Schistosomiasis - Therapeutics under Investigation by Universities/Institutes
    Schistosomiasis - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Schistosomiasis - Products under Development by Companies
    Schistosomiasis - Products under Investigation by Universities/Institutes
    Schistosomiasis - Companies Involved in Therapeutics Development
    Kancera AB
    LondonPharma Ltd
    Merck KGaA
    Salvensis
    Schistosomiasis - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    BDM-I - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EDE-1102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    intestinal schistosomiasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    intestinal schistosomiasis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    L-Praziquantel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Schistosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Schistosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Schistosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Schistosomiasis - Dormant Projects
    Schistosomiasis - Product Development Milestones
    Featured News & Press Releases
    Aug 23, 2013: BioDiem US patent for skin and wound infections
    Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
    Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
    Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
    Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Schistosomiasis, H2 2016
    Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Schistosomiasis - Pipeline by Kancera AB, H2 2016
    Schistosomiasis - Pipeline by LondonPharma Ltd, H2 2016
    Schistosomiasis - Pipeline by Merck KGaA, H2 2016
    Schistosomiasis - Pipeline by Salvensis, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Schistosomiasis - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Schistosomiasis, H2 2016
    Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report